

7

artificial gastric juices (pH 1, HCl). The compositions are stable, e.g. for 2 years at room temperature,

If desired larger capsules containing 534.3 mg MFA mono sodium salt may be made in analogous manner, reducing the amount of lactose. These are well tolerated in clinical trials. 5

#### EXAMPLE 2:

Capsules of size 1 are made up as in Example 1. A solution for enteric coating was made up as follows:

Hydroxypropyl methyl cellulose	270 g
phthalate (HP50)	
Triacetin	30 g
Acetone	900 g
Ethanol	1800 g

600 g of this enteric coating solution was used for 1 kg of capsules (ca. 2400). The amount of coating applied to each capsule was about 25 mg giving a film thickness of 5–6 mg/cm<sup>2</sup>. 20

What is claimed is:

1. A pharmaceutical composition comprising a mycophenolate salt, the composition being formulated to disintegrate selectively in the intestinal tract to release mycophenolate there.

8

2. A method of immunosuppressing a subject which comprises administering a therapeutically effective amount of a composition of claim 1 to a subject in need of such immunosuppression, optionally with the simultaneous or separate administration another immunosuppressant, wherein the composition has an enteric coating.

3. A composition containing a composition of claim 1 and another immunosuppressant for simultaneous, sequential or separate administration, wherein the composition has an enteric coating.

4. A composition according to claim 1 wherein the salt is the mono-sodium salt.

5. A composition according to claim 1 wherein said composition further comprises another immunosuppressant. 15

6. The pharmaceutical composition of claim 1 wherein said composition has an enteric coating and is suitable as an immunosuppressant medicament.

7. The pharmaceutical composition of claim 6 wherein said composition further comprises a second immunosuppressant.

8. The pharmaceutical composition of claim 7 wherein said second immunosuppressant is cyclosporin.

\* \* \* \* \*